Peter Brünker

Title: Innovations of Peter Brünker in Antigen Binding Molecules

Introduction

Peter Brünker is a notable inventor based in Hittnau, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding molecules. With a total of two patents to his name, his work focuses on enhancing therapeutic properties of antibodies.

Latest Patents

Brünker's latest patents include innovations related to polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function. The first patent details nucleic acids encoding recombinant monoclonal antibodies, including chimeric, primatized, or humanized antibodies specific for human CD20. This invention encompasses isolated polynucleotides that encode polypeptides with specific sequences, as well as vectors and host cells that incorporate these nucleic acid molecules. The second patent also focuses on antigen binding molecules, emphasizing methods for producing these ABMs and their application in disease treatment. Both patents highlight the importance of modified glycosylation for improved therapeutic properties.

Career Highlights

Peter Brünker is currently associated with Roche Glycart AG, a company renowned for its advancements in antibody technology. His work at Roche has allowed him to explore innovative solutions in the field of monoclonal antibodies, contributing to the development of effective treatments.

Collaborations

Brünker has collaborated with notable colleagues such as Pablo Umaña and Tobias Suter. Their combined expertise has fostered advancements in the research and development of antibody-based therapies.

Conclusion

Peter Brünker's contributions to the field of biotechnology, particularly in the development of antigen binding molecules, showcase his innovative spirit and dedication to improving therapeutic options. His patents reflect a commitment to advancing medical science through cutting-edge research.